Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey
Open Access
- 16 April 2015
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 29 (10) , 2002-2010
Abstract
Background: Available literature on psoriasis and psoriatic arthritis (PsA) demonstrates a tremendous burden of disease and suggests underdiagnosis and undertreatment.Objective: To obtain real‐world physician perspectives on the impact of psoriasis and PsA and its treatment on patients' daily lives, including perceptions of, and satisfaction with, current therapies.Methods: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) surveyed dermatologists (n = 391) and rheumatologists (n = 390) in North America (Canada and the United States) and Europe (France, Germany, Italy, Spain and United Kingdom).Results: Dermatologists classified 20.3% and 25.7% of their patients as having severe psoriasis and severe PsA respectively; rheumatologists indicated that 48.4% of their PsA patients had active disease. Of the psoriasis patients complaining of joint pain, only 33.0% had a diagnosis of PsA. An impact on daily activities or social/emotional well‐being was recognized by 57.2% to 79.3% of physicians. In patients with moderate‐to‐severe psoriasis, dermatologists reported 74.9% were receiving topical therapy, 19.5% conventional oral therapy and 19.6% biologics. Dermatologists and rheumatologists reported similar rates of topical (≈45%) and biologic (≈30%) therapy utilization for their PsA patients; conventional oral therapy was more often prescribed by rheumatologists (63.4%) vs. dermatologists (35.2%). Reasons for not initiating or maintaining systemic therapies were related to concerns about long‐term safety, tolerability, efficacy and costs (biologics).Conclusion: Physicians in North America and Europe caring for patients with psoriasis and PsA acknowledge unmet treatment needs, largely concerning long‐term safety/tolerability and efficacy of currently available therapies; evidence suggests underdiagnosis of PsA and undertreatment of psoriasis among dermatologists.Keywords
Funding Information
- Celgene Corporation
This publication has 16 references indexed in Scilit:
- Prevalencia de la psoriasis en España en la era de los agentes biológicosActas Dermo-Sifiliograficas, 2014
- Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis SurveyJournal of the American Academy of Dermatology, 2014
- Psoriasis prevalence among adults in the United StatesJournal of the American Academy of Dermatology, 2014
- Psoriasis Comorbidities: Results from the National Psoriasis Foundation Surveys 2003 to 2011Dermatology, 2012
- Co-morbidity and Age-related Prevalence of Psoriasis: Analysis of Health Insurance Data in GermanyActa Dermato-Venereologica, 2010
- The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy peopleHealth and Quality of Life Outcomes, 2009
- The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: Results from NHANES 2003-2004Journal of the American Academy of Dermatology, 2009
- Guidelines of care for the management of psoriasis and psoriatic arthritisJournal of the American Academy of Dermatology, 2008
- Psoriatic arthritis: epidemiology, clinical features, course, and outcomeAnnals of the Rheumatic Diseases, 2005
- Prevalence of psoriasis in Spain (Epiderma Project: phase I)Journal of the European Academy of Dermatology and Venereology, 2001